Author Index Volume 28 (2016)
The issue number is given in front of the page numbers
Abi-Jaoude, E., see Le Noury, J. (3) 143–161
Afifi, S., see Peymani, P. (1) 25–31
Alvarez, P.A., D.T. Nguyen, R. Schutt, C. Ganduglia, J.D. Estep, E.A. Graviss and D. Putney, In-hospital use of non-steroidal anti-inflammatory drugs in patients with heart failure in academic centers in the United States (4) 181–188
Amsterdam, J.D., see Jureidini, J.N. (1) 33–43
Awodele, O., A. Ibrahim and P. Orhii, Patterns of adverse drug reaction signals in NAFDAC Pharmacovigilance activities from September to November, 2014 (1) 13–23
Baldo, V., see Buja, A. (3) 163–170
Bassi, P., see Ogunleye, O.O. (2) 77–91
Buja, A., A.M. Saieva, A. Vinelli, R.M. Cacco, K. Ottolitri, E. De Battisti, C. Dario and V. Baldo, Adverse event reporting and patient safety at a University Hospital: Mapping, correlating and associating events for a data-based patient risk management (3) 163–170
Cacco, R.M., see Buja, A. (3) 163–170
Cohen, D., see Hughes, S. (2) 101–114
Cruz, R.S., see dos Reis, C. (1) 45–60
Danborg, P.B., see Simonsen, A.L. (1) 1–12
Dario, C., see Buja, A. (3) 163–170
De Battisti, E., see Buja, A. (3) 163–170
Dias, J.J., see Mehta, S. (2) 65–75
dos Reis, C., R. Teixo, F. Mendes and R.S. Cruz, Biosimilar medicines – Review (1) 45–60
Ekoja, M., see Ogunleye, O.O. (2) 77–91
El-Enein, N.Y.A., see Zaghloul, A.A. (2) 93–99
Enwere, O., see Ogunleye, O.O. (2) 77–91
Estep, J.D., see Alvarez, P.A. (4) 181–188
Falade, C., see Ogunleye, O.O. (2) 77–91
Ganduglia, C., see Alvarez, P.A. (4) 181–188
Gøtzsche, P.C., see Simonsen, A.L. (1) 1–12
Graviss, E.A., see Alvarez, P.A. (4) 181–188
Grech, V., Response to a Letter to the Editor (3) 175 –176
Healy, D., J. Le Noury and D. Mangin, Links between serotonin reuptake inhibition during pregnancy and neurodevelopmental delay/spectrum disorders: A systematic review of epidemiological and physiological evidence (3) 125–141
Healy, D., see Le Noury, J. (3) 143–161
Heydari, S.T., see Peymani, P. (1) 25–31
Hughes, S., D. Cohen and R. Johnson, Adverse event assessment methods in published trials of psychotropic drugs: Poor reporting and neglect of emerging safety concerns (2) 101–114
Ibrahim, A., see Awodele, O. (1) 13–23
Isah, A., see Ogunleye, O.O. (2) 77–91
Jargin, S.V., Concerning a Letter to the Editor (3) 171–174
Johnson, R., see Hughes, S. (2) 101–114
Jørgensen, K.J., see Ziganshina, L.E. (4) 221–226
Jureidini, J., see Le Noury, J. (3) 143–161
Jureidini, J.N., J.D. Amsterdam and L.B. McHenry, The citalopram CIT-MD-18 pediatric depression trial: Deconstruction of medical ghostwriting, data mischaracterisation and academic malfeasance (1) 33–43
Kapp, M.B., Defensive medicine: No wonder policymakers are confused (4) 213–219
Kapp, M.B., Front office staff as medical educators, risk creators, and risk managers (1) 61–64
Kilani, J., see Ogunleye, O.O. (2) 77–91
Kolfschoten, J., see Rolfes, L. (2) 115–123
Kooijman, M., see Rolfes, L. (2) 115–123
Kwon, C.S., E. Seoane-Vazquez and R. Rodriguez-Monguio, FDA safety actions for antidiabetic drugs marketed in the US, 1980–2015 (4) 197–211
Lankarani, K.B., see Peymani, P. (1) 25–31
Le Noury, J., J.M. Nardo, D. Healy, J. Jureidini, M. Raven, C. Tufanaru and E. Abi-Jaoude, Study 329 continuation phase: Safety and efficacy of paroxetine and imipramine in extended treatment of adolescent major depression (3) 143–161
Le Noury, J., see Healy, D. (3) 125–141
Maharlouei, N., see Peymani, P. (1) 25–31
Mangin, D., see Healy, D. (3) 125–141
McHenry, L.B., see Jureidini, J.N. (1) 33–43
Mehta, S., H.P. Singh and J.J. Dias, Effect of patient safety incident review and reflection in an extended morbidity and mortality meeting (2) 65–75
Mendes, F., see dos Reis, C. (1) 45–60
Namazi, S., see Peymani, P. (1) 25–31
Nardo, J.M., see Le Noury, J. (3) 143–161
Nguyen, D.T., see Alvarez, P.A. (4) 181–188
Nouraei, H., see Peymani, P. (1) 25–31
Obiako, R., see Ogunleye, O.O. (2) 77–91
Obodo, J., see Ogunleye, O.O. (2) 77–91
Odesanya, R., see Ogunleye, O.O. (2) 77–91
Ogundele, S.O., see Ogunleye, O.O. (2) 77–91
Ogunleye, O.O., I.A. Oreagba, C. Falade, A. Isah, O. Enwere, S. Olayemi, S.O. Ogundele, R. Obiako, R. Odesanya, P. Bassi, J. Obodo, J. Kilani and M. Ekoja, Medication errors among health professionals in Nigeria: A national survey (2) 77–91
Olayemi, S., see Ogunleye, O.O. (2) 77–91
Oreagba, I.A., see Ogunleye, O.O. (2) 77–91
Orhii, P., see Awodele, O. (1) 13–23
Ottolitri, K., see Buja, A. (3) 163–170
Peymani, P., R. Tabrizi, S. Afifi, S. Namazi, S.T. Heydari, M.K. Shirazi, H. Nouraei, E. Sadeghi, K.B. Lankarani and N. Maharlouei, Knowledge, attitude and practice of General Practitioners towards adverse drug reaction reporting in South of Iran, Shiraz (Pharmacoepidemiology report) (1) 25–31
Putney, D., see Alvarez, P.A. (4) 181–188
Rahman, S.A., see Zaghloul, A.A. (2) 93–99
Raven, M., see Le Noury, J. (3) 143–161
Rodriguez-Monguio, R., see Kwon, C.S. (4) 197–211
Rolfes, L., J. Kolfschoten, F. van Hunsel, M. Kooijman and E. van Puijenbroek, Actions in response to drug safety signals arising from a spontaneous reporting system: Retrospective study in The Netherlands (2) 115–123
Sadeghi, E., see Peymani, P. (1) 25–31
Saieva, A.M., see Buja, A. (3) 163–170
Scherb, H., Comment on a Letter to the Editor (3) 177 –180
Schutt, R., see Alvarez, P.A. (4) 181–188
Seoane-Vazquez, E., see Kwon, C.S. (4) 197–211
Shirazi, M.K., see Peymani, P. (1) 25–31
Simonsen, A.L., P.B. Danborg and P.C. Gøtzsche, Persistent sexual dysfunction after early exposure to SSRIs: Systematic review of animal studies (1) 1–12
Singh, H.P., see Mehta, S. (2) 65–75
Tabrizi, R., see Peymani, P. (1) 25–31
Teixo, R., see dos Reis, C. (1) 45–60
Tufanaru, C., see Le Noury, J. (3) 143–161
van Hunsel, F., see Rolfes, L. (2) 115–123
van Puijenbroek, E., see Rolfes, L. (2) 115–123
Vinelli, A., see Buja, A. (3) 163–170
Yaxley, J., Common analgesic agents and their role in analgesic nephropathy: A commentary of the evidence (4) 189–196
Zaghloul, A.A., S.A. Rahman and N.Y.A. El-Enein, Obligation towards medical errors disclosure at a tertiary care hospital in Dubai, UAE (2) 93–99
Ziganshina, L.E. and K.J. Jørgensen, The first ever Cochrane event in Russia and Russian speaking countries – Cochrane Russia Launch – Evidence-based medicine: Achievements and barriers (QiQUM 2015) International Conference, Kazan, December 7-8, 2015 (4) 221–226
